Section 296-20-03056. Opioid authorization requirement for the subacute phase (6-12 weeks).  


Latest version.
  • Before the department or self-insurer authorizes payment for opioids beyond the acute phase, the provider must perform and document the following:
    • Verify that the worker had clinically meaningful improvement in function and pain with the use of opioids in the acute phase.
    • If indicated, use a validated instrument to screen the worker for comorbid psychiatric conditions (e.g., depression, anxiety, or post traumatic stress disorder) which may impact the response to opioid treatment.
    • Verify that the worker has no contraindication to the use of opioids.
    • Access the state's prescription monitoring program data base, if available, to ensure that the controlled substance history is consistent with the prescribing record and the worker's report.
    • Use a validated screening instrument to verify the absence of a current substance use disorder (excluding nicotine) or a history of opioid use disorder.
    • Administer a baseline urine drug test to verify the absence of cocaine, amphetamines, alcohol, and nonprescribed opioids.
    • Verify that the worker has no evidence of or is not at high risk for serious adverse outcomes from opioid use.
    [Statutory Authority: RCW 51.04.020 and 51.04.030. WSR 13-12-024, § 296-20-03056, filed 5/28/13, effective 7/1/13.]
RCW 51.04.020 and 51.04.030. WSR 13-12-024, § 296-20-03056, filed 5/28/13, effective 7/1/13.